BioSpace News Archive

Akero Therapeutics, Inc. announced that management will present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 4:00 p.m. E.T.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will present at the upcoming Jefferies Healthcare Conference being held on June 8-10, 2022, in New York, NY.

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced its participation in the LD Micro Invitational XII Conference on June 7-9, 2022.

IntelGenx Technologies Corp. announces that it intends to issue shares of common stock of the Company in payment of the outstanding C$5,450,000 aggregate principal amount of the Company’s convertible unsecured subordinated debentures due June 30, 2022 and issue 573,684 Shares at a deemed price of C$0.38 per Share in payment of an aggregate of C$218,000 interest due on the Debentures as of June 30, 2022.

ReAlta Life Sciences, Inc. (“ReAlta”) a clinical stage, rare disease company addressing life-threatening diseases through harnessing the power of the immune system, today announced the dosing of the first patient in its Phase 1b Inhaled- lipopolysaccharide (LPS) challenge clinical trial in healthy volunteers to support development of RLS-0071 in severe asthma.

Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pirfenidone to its oral solid products portfolio.

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort I of their Phase I clinical trial.

Standigm Inc. (“Standigm”), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research.

Animal studies have been used extensively over the years to model the effect of medicinal compounds on the human body.

Harbour BioMed (the “Company”, HKEX: 02142), today announced the progress of its dual MOA of CTLA-4 inhibition and Treg depletion, next-generation fully human heavy-chain antibody (HBM4003) with studies of monotherapy and combination therapy with anti-PD-1 antibody.